Status
Conditions
Treatments
About
This is a prospective non-interventional observational study to evaluate the treatment of moderately active RA patients in every day clinical practice in Austria. Patients will be observed over 52 weeks. The primary endpoint will be percentage of patients who reach CDAI remission after 24 weeks.
Full description
Non-interventional observational study, national, multicenter prospective non-interventional study (NIS) as defined by the Austrian Drug Law § 2a Section 3 N/A
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Any contraindication according to the Austrian SmPC, which includes:
A hypersensitivity to any component of Etanercept, active tuberculosis or any other serious infection.
Patient has previously participated in this study.
111 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal